Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 4, 2013, Pages 526-531

  Van Den Hof, S ^a,b   Tursynbayeva, A ^a,c   Abildaev, T ^c   Adenov, M ^c   Pak, S ^a   Bekembayeva, G ^c   Ismailov, S ^d  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c National Center for Tuberculosis Problems   (Kazakhstan)

^d Global Fund Against AIDS   (Kazakhstan)

Author keywords

Drug resistance; HIV; Kazakhstan; MDR TB; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALCOHOLISM; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG USE; FEMALE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; KAZAKHSTAN; LUNG TUBERCULOSIS; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR; SPUTUM SMEAR; URBAN POPULATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COINFECTION; DRUG USERS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; KAZAKHSTAN; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SPUTUM; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84875449036     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0703     Document Type: Article

References (22)

1. Wells C D, Cegielski J P, Nelson L J, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196 (Suppl 1): S86-S10-7.
2. Zignol M, van Gemert W, Falzon D, et al. Surveillance of antituberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D.
3. World Health Organization. Multidrug and extensively drugresistant tuberculosis (M/XDR-TB). WHO global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 201-0.
4. Suchindran S, Brouwer E S, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS ONE 2009; 4: e556-1.
5. Gandhi N R, Moll A, Sturm A W, et al. Extensively drugresistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-158-0.
6. Coker R J. Review: multidrug-resistant tuberculosis: public health challenges. Trop Med Int Health 2004; 9: 25-4-0.
7. Lawn S D, Wood R, De Cock K M, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10: 489-49-8.
8. Dye C, Williams B G, Espinal M A, Raviglione M C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-204-6.
9. World Health Organization Global Health Observatory Data Repository. Prevalence of HIV among adults aged 15 to 49 (%). Geneva, Switzerland: WHO, 2012. http://apps.who.int/ghodata/?vid=22100 Accessed July 201-2.
10. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva, Switzerland: UNAIDS, 201-0.
11. Kubica T, Agzamova R, Wright A, et al. The Beijing genotype is a major cause of drug-resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis 2005; 9: 646-65-3.
12. World Health Organization. Anti-tuberculosis drug resistance in the world: third global report. WHO/HTM/TB/2004.343. Geneva, Switzerland: WHO, 200-4.
13. Klinkenberg E, van den Hof S, Tursynbayeva A, et al. Integration of HIV testing in tuberculosis drug resistance surveillance in Kazakhstan and Kenya. Int J Tuberc Lung Dis 2012; 16: 615-61-7.
14. Statistics Agency of the Republic of Kazakhstan. Astana City, Kazakhstan: Statistics Agency of the Republic of Kazakhstan, 2008. http://www.eng.stat.kz/ digital/population/pages/default. aspx Accessed July 201-2.
15. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-143-1.
16. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7: 81-8-7.
17. Sergeev R, Colijn C, Murray M, Cohen T, et al. Modeling the dynamic relationship between HIV and the risk of drugresistant tuberculosis. Sci Transl Med 2012; 4: 135ra6-7.
18. Deiss R G, Rodwell T C, Garfein R S. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009; 48: 72-8-2.
19. Miller A C, Gelmanova I Y, Keshavjee S, et al. Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation. Int J Tuberc Lung Dis 2012; 16: 891-89-6.
20. Gelmanova I Y, Taran D V, Mishustin S P, Golubkov A A, Solovyova A V, Keshavjee S. 'Sputnik': a programmatic approach to improve tuberculosis treatment adherence and outcome among defaulters. Int J Tuberc Lung Dis 2011; 15: 1373-137-9.
21. Perkins M D, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 2007; 196 (Suppl 1): S15-S2-7.
22. Hasker E, Khodjikhanov M, Usarova S, Yuldasheva U, Uzakova G, Veen J. Health-care seeking behaviour for TB symptoms in two provinces of Uzbekistan. Trop Doct 2008; 38: 107-10-9.